Adeniji Nia1, Renumathy Dhanasekaran2. 1. Stanford School of Medicine, Stanford, CA. 2. Division of Gastroenterology and Hepatology, Stanford, CA.
Abstract
INTRODUCTION: Hepatocellular carcinoma (HCC) is a leading cause of cancer related mortality in the world and it has limited treatment options. Understanding the molecular drivers of HCC is important to develop novel biomarkers and therapeutics. PURPOSE OF REVIEW: HCC arises in a complex background of chronic hepatitis, fibrosis and liver regeneration which lead to genomic changes. Here, we summarize studies that have expanded our understanding of the molecular landscape of HCC. RECENT FINDINGS: Recent technological advances in next generation sequencing (NGS) have elucidated specific genetic and molecular programs involved in hepatocarcinogenesis. We summarize the major somatic mutations and epigenetic changes have been identified in NGS-based studies. We also describe promising molecular therapies and immunotherapies which target specific genetic and epigenetic molecular events. SUMMARY: The genomic landscape of HCC is incredibly complex and heterogeneous. Promising new developments are helping us decipher the molecular drivers of HCC and leading to new therapies.
INTRODUCTION: Hepatocellular carcinoma (HCC) is a leading cause of cancer related mortality in the world and it has limited treatment options. Understanding the molecular drivers of HCC is important to develop novel biomarkers and therapeutics. PURPOSE OF REVIEW: HCC arises in a complex background of chronic hepatitis, fibrosis and liver regeneration which lead to genomic changes. Here, we summarize studies that have expanded our understanding of the molecular landscape of HCC. RECENT FINDINGS: Recent technological advances in next generation sequencing (NGS) have elucidated specific genetic and molecular programs involved in hepatocarcinogenesis. We summarize the major somatic mutations and epigenetic changes have been identified in NGS-based studies. We also describe promising molecular therapies and immunotherapies which target specific genetic and epigenetic molecular events. SUMMARY: The genomic landscape of HCC is incredibly complex and heterogeneous. Promising new developments are helping us decipher the molecular drivers of HCC and leading to new therapies.
Authors: Ailinh L Do; Carrie R Wong; Long H Nguyen; Vincent G Nguyen; Huy Trinh; Mindie H Nguyen Journal: J Clin Gastroenterol Date: 2014-08 Impact factor: 3.062
Authors: Lindsey N Kent; Sooin Bae; Shih-Yin Tsai; Xing Tang; Arunima Srivastava; Christopher Koivisto; Chelsea K Martin; Elisa Ridolfi; Grace C Miller; Sarah M Zorko; Emilia Plevris; Yannis Hadjiyannis; Miguel Perez; Eric Nolan; Raleigh Kladney; Bart Westendorp; Alain de Bruin; Soledad Fernandez; Thomas J Rosol; Kamal S Pohar; James M Pipas; Gustavo Leone Journal: J Clin Invest Date: 2017-01-30 Impact factor: 14.808
Authors: Matthew J Reilley; Patricia McCoon; Carl Cook; Paul Lyne; Razelle Kurzrock; Youngsoo Kim; Richard Woessner; Anas Younes; John Nemunaitis; Nathan Fowler; Michael Curran; Qinying Liu; Tianyuan Zhou; Joanna Schmidt; Minji Jo; Samantha J Lee; Mason Yamashita; Steven G Hughes; Luis Fayad; Sarina Piha-Paul; Murali V P Nadella; Xiaokun Xiao; Jeff Hsu; Alexey Revenko; Brett P Monia; A Robert MacLeod; David S Hong Journal: J Immunother Cancer Date: 2018-11-16 Impact factor: 13.751